Boston Scientific Cuts Forecast on Product Slowdown and Competition

Boston Scientific (NYSE: BSX) has cut its fiscal 2026 outlook due to a slowdown in the U.S. Watchman heart implant market and increased competition in the EP market, causing its stock to trade lower. Despite beating Q2 revenue and adjusted earnings estimates, the company lowered its sales and earnings per share guidance for the full fiscal year. In response, Boston Scientific has initiated a restructuring plan aimed at generating significant cost savings and improving its growth profile by 2028.